FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

In Partnership With:

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Roy S. Herbst, MD, PhD, about the FDA approval of adjuvant pembrolizumab (Keytruda) in patients with non–small cell lung cancer (NSCLC). Dr Herbst is the Ensign Professor of Medicine (Medical Oncology), professor of pharmacology, director of the center for thoracic cancers, and assistant dean for translational research in the Office of the Dean at the Yale School of Medicine, as well as the chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital and the deputy director of Yale Cancer Center in New Haven, Connecticut.

On January 26, 2023, the FDA approved pembrolizumab as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage IB, II, or IIIA NSCLC. The approval was backed by the results of the phase 3 PEARLS/KEYNOTE-091 trial (NCT02504372), in which patients who received adjuvant chemotherapy achieved a median disease-free survival of 58.7 months with pembrolizumab vs 34.9 months with placebo.

In our exclusive interview, Dr Herbst discussed the significance of this approval, key efficacy and safety data from KEYNOTE-091, and future research efforts that may further improve outcomes in this population.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Brian Henick, MD
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Brian Mitzman, MD, FACS, FCCP
In this sixth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the consideration of adverse effects related to treatment with TKIs patients in non–small cell lung cancer.
David Rimm, MD, PhD
 In this fifth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses instances where oral etoposide could be utilized for patients with small cell lung cancer.
Khaled Hassan, MD
David A. Braun, MD, PhD
In this fourth episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the management of immune-related adverse effects and the goal of mitigating steroid use for patients with lung cancer.
Yvonne Chao, MD, PhD
Related Content